United States: Proskauer Represents Celgene In Pricing Of $3 Billion Of Notes
Last Updated: November 10 2017

November 2, 2017 (NEW YORK) – Proskauer represented long-time client Celgene Corporation in the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $3 billion. Of these notes, $750 million will mature in 2023, $1 billion will mature in 2027 and $1.25 billion will mature in 2047. The 2.750 percent notes due 2023, the 3.450 percent notes due 2027 and the 4.350 percent notes due in 2047 were priced to yield 2.762 percent, 3.468 percent and 4.366 percent, respectively.  

Barclays Capital Inc., Credit Suisse Securities (USA) LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers and representatives of the several underwriters.

Proskauer has represented Celgene, one of the world's largest biopharmaceutical companies, in all of its capital markets transactions since the company's inception in 1986.

The Proskauer team was led by partners Frank Lopez and Steven Gruberg (Capital Markets); partner Robert Cantone; and associates Caitlin O'Hern and William Majeski (Corporate).

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Allan Bloom, Laura Fant
By Andrew Santana
By Allan Bloom, Mark Batten
By Proskauer Rose LLP
By Lawrence Weinstein, Alexander Kaplan, Evelyn Pang
By Allan Bloom, Laura Fant
By Anthony Oncidi, Travis Hall
By Mark Theodore
By Jeffrey Neuburger
By Proskauer Rose LLP
Tools
Print
Font Size:
Translation
Channels